Many scientific studies present removal efficiencies for pharmaceuticals in laboratory-, pilot-, and full-scale wastewater treatment plants, based on observations that may be impacted by theoretical and methodological approaches used. In this Critical Review, we evaluated factors influencing observed removal efficiencies of three antibiotics (sulfamethoxazole, ciprofloxacin, tetracycline) in pilot-and full-scale biological treatment systems. Factors assessed include (i) retransformation to parent pharmaceuticals from e.g., conjugated metabolites and analogues, (ii) solid retention time (SRT), (iii) fractions sorbed onto solids, and (iv) dynamics in influent and effluent loading. A recently developed methodology was used, relying on the comparison of removal efficiency predictions (obtained with the Activated Sludge Model for Xenobiotics (ASM-X)) with representative measured data from literature. By applying this methodology, we demonstrated that (a) the elimination of sulfamethoxazole may be significantly underestimated when not considering retransformation from conjugated metabolites, depending on the type (urban or hospital) and size of upstream catchments; (b) operation at extended SRT may enhance antibiotic removal, as shown for sulfamethoxazole; (c) not accounting for fractions sorbed in influent and effluent solids may cause slight underestimation of ciprofloxacin removal efficiency. Using tetracycline as example substance, we ultimately evaluated implications of effluent dynamics and retransformation on environmental exposure and risk prediction.
■ INTRODUCTION
Biological wastewater treatment plants (WWTPs) have a crucial role in the mitigation of the risk posed by the release of pharmaceuticals in receiving environmental bodies. The elimination of pharmaceuticals in conventional WWTPs is presently considered insufficient, and a number of substances of concern for the aquatic environment have been identified at national 1,2 and regional levels. 3 Among existing pharmaceutical classes, research has focused on antibiotics because of their ubiquitous usage, their overall recalcitrance to biological wastewater treatment, and more recently, antibiotic resistance spread by WWTP emissions. 4−7 Because of the comparably high costs and the uncertainty inherent in the analysis of pharmaceuticals, simulation models represent an appealing option to investigate their fate and elimination in biological WWTPs. Two recent review articles 8, 9 summarized the approaches used for fate prediction of xenobiotic trace chemicals in wastewater, including pharmaceuticals. Nevertheless, adequate assessment of pharmaceutical elimination in biological WWTPs still remains a challenge, considering the high variability of measured removal efficiencies presented in literature for the same substance. 6,10−13 Thus, combining modeling and experimental/analytical efforts offers the opportunity for a thorough understanding of elimination mechanisms in WWTPs. It also represents a valuable option for decision support to operators and legislators, given the progressive implementation of WWTP upgrade measures to reduce emissions of trace chemicals. 14−17 In the last three decades, ever since pharmaceuticals were detected in aqueous media, several review articles on the fate of pharmaceuticals and, more specifically, antibiotics during wastewater treatment have been published. 5,6,10,12,18− 31 The main objective of this study was to complement previous assessments by critically evaluating factors influencing the elimination of antibiotics and by testing a model-based methodology to identify the influence of such factors. The assessment focused on the influence of (i) retransformation to parent antibiotics via, for example, metabolite deconjugation, (ii) solid retention time (SRT) in secondary treatment, (iii) fractions sorbed onto influent and effluent solids, and (iv) intrinsic dynamics in influent and effluent loading. The developed methodology relies on the generalization of the calibrated Activated Sludge Modeling Framework for Xenobiotics (ASM-X 32−34 ) with full-scale international removal efficiency data thoroughly selected from peer reviewed literature. The methodology, already tested for diclofenac and carbamazepine, 33 was further considered for three antibiotics (sulfamethoxazole, SMX; ciprofloxacin, CIP; tetracycline, TCY), for which the model had already been calibrated and evaluated with batch and fullscale experimental data, respectively. 32 An overview of the therapeutic use of the selected antibiotics is provided in the Supporting Information.
■ FACTORS AND PROCESSES INFLUENCING
ANTIBIOTIC REMOVAL IN WWTPS Retransformation Processes. In the following subsections, we assess in detail a number of processes responsible for "negative" removal efficiencies 35 observed in full-scale WWTPs for parent pharmaceuticals. A critical overview of processes, not traditionally accounted for when assessing pharmaceutical fate, is provided to propose a more integrated approach to fate assessment.
Deconjugation of Metabolites. The human metabolism of administered pharmaceuticals involves two types of mechanisms, that is, functionalization reactions (e.g., oxidation, hydroxylation, reduction, mostly catalyzed by CYP450 enzymes) and conjugation reactions (e.g., glucuronidation, sulfation, acetylation). The latter mechanisms increase the polarity of organic molecules to facilitate their excretion. The traditional distinction of these reactions as Phase I and Phase II metabolism, respectively, has been lately questioned, as direct conjugation of parent pharmaceuticals frequently occurs. 36, 37 Conjugated metabolites of parent pharmaceuticals can undergo retransformation back to the parent form following cleavage of the conjugated moiety. Importantly, this type of conjugates can represent up to one-quarter (22%) of first-step pharmaceutical metabolites, 37 indicating a potential for the formation of parent forms after excretion.
Microbial deconjugation of human metabolites to parent forms has been hypothesized or observed in wastewater for estrogens, 38−40 carbamazepine, 33,41−44 and its functionalized metabolites 44−46 and diclofenac. 33, 47, 48 For the latter two substances, deconjugation was considered to explain concentration increases from WWTP influent to effluent. Although the significance of deconjugation during wastewater treatment has been acknowledged, detailed empirical evidence is still scarce, being limited to estrogens, because of analytical challenges. 49−52 With respect to the antibiotics considered in this study, the metabolism has been widely investigated, allowing for the identification of potentially retransformable excreted forms. A detailed description of the metabolism and excretion of SMX, CIP and TCY and their metabolites is presented in the Supporting Information (Figures S1−S4 and Table S1 ). The human metabolism of SMX involves the excretion of acetylated (N 4 -acetyl-SMX) and glucuronide (SMX-N 1 -Glu, SMX-2′-Glu) conjugates of the parent substance, which combined in urine account from 50% up to 75% of an administered dose of SMX ( Figure S4 and Table S1 ). 53, 54 Extensive literature exists on the deconjugation of the major metabolite, N 4 -acetyl-SMX, during wastewater treatment. 55−59 Retransformation of acetylated metabolites back to parent forms has also been observed for other sulfonamides in aqueous media. 60 More recently, SMX-N 1 -Glu was detected in preclarified 61 and final WWTP effluent 62 and receiving surface water bodies, 63 possibly indicating its persistence (as for other N-glucuronide pharmaceutical metabolites 44 ). Conversely, almost complete elimination (>90%) was observed during secondary treatment 61 and comparably fast microbial deconjugation of SMX-N 1 -Glu occurred in water-sediment tests. 64 Excreted conjugated metabolites of CIP include sulfo-CIP and N-formyl-CIP, the former being the main conjugated metabolite (up to 17% of an administered dose). 65, 66 Minor excretion of the glucuronide conjugate (CIP-Glu) has also been reported, 67 although this metabolite has never been identified in wastewater. To the authors' knowledge, microbial deconjugation of sulfo-CIP in aqueous media has not been investigated, but can be postulated in analogy with other sulfate metabolites (e.g., of natural and synthetic estrogens 40, 68, 69 ). Orally and intravenously administered TCY undergoes limited metabolism in humans, being excreted mainly in unchanged form ( Figure S1 ). 70−72 No formation of conjugated metabolites has been reported.
Abiotic Retransformation of Metabolites and Transformation Products. Minor excretion (5%) of TCY in the form of the optical isomer 4-epi-tetracycline (4-epi-TCY) has been reported. 73, 74 4-epi-TCY has been also identified as abiotic transformation product of TCY in aqueous solution, 75 activated sludge, 76 and manure. 77−79 In liquid media, epimerization of TCY was shown to be reversible, mostly occurring under acidic and neutral conditions. 77, 80 Epimerization is catalyzed by the presence of anions, 80 whereas reverse epimerization is facilitated in the presence of divalent cations at pH > 6. 81, 82 Up to 70% abiotic retransformation of 4-epimers of TCY and its analogues was shown in soil and activated sludge at pH = 8.1 and in the presence of magnesium and calcium ions. 76 Reversible epimerization, with formation of TCY from 4-epi-TCY, is thus identifiable as abiotic retransformation process. 4-epi-TCY concentration was quantified in two hospital effluents at μg L −1 levels, 83 being 11% and 35% of corresponding TCY concentration. Comparable concentrations of TCY and 4-epi-TCY (∼100 ng L −1 ) were also measured in the influent of a municipal WWTP, where almost complete removal of the two substances was reported to occur via sorption onto activated sludge. 84 Nitration and nitrosation are common abiotic transformation mechanisms for trace chemicals containing aromatic groups. 85 The formation of nitrated products was shown in pure and mixed nitrifying cultures for the estrogen 17α-ethinyl estradiol (EE2) 86−89 and acetaminophen, 90 being associated with significant accumulation of nitrite or peroxynitrite and acidic pH conditions. Nitrated and nitrosated derivatives were further identified and quantified (at low ng L −1 levels) in full-scale WWTPs for SMX 91 and diclofenac. 91−93 Although nitration and nitrosation appear of limited importance during conventional treatment of domestic wastewater, 85−89 these mechanisms may be relevant to the treatment of high strength reject water and/or in deammonification and nitrite shunt processes, where nitrite accumulation is more likely to occur. Notably, parent SMX was shown to be abiotically formed from its nitrosated (via photolysis) 63 and nitrated 94 derivatives.
Formation from Analogues and Structurally Related Chemicals. Pharmaceuticals and their human metabolites can be additionally formed from other commercial chemicals (a) as a result of human metabolism and (b) as products of biological transformation processes during, for example, wastewater treatment. Formation typically occurs from substances exhibiting structural similarity to the formed pharmaceutical. Examples are oxazepam, a benzodiazepine pharmaceutical and a human metabolite of the analogues diazepam and temazepam, and atenolol acid, a human metabolite of metoprolol and a transformation product of atenolol. 95−97 Formation from other commercial chemicals via metabolism (following veterinary use) and environmental biodegradation have been reported for CIP and TCY. CIP was observed to be a metabolite (up to 47% of the administered dose 98−100 ), fungal degradation product, 101 and photolysis product 102 of enrofloxacin. Rolitetracycline, a tetracycline analogue used for veterinary therapy, can be metabolized to TCY. 103 Release from Faecal Matter. Concentration increases between the influent and the effluent of a primary clarifier were reported for fluoroquinolones, including CIP, 104,105 and macrolides, 56 possibly resulting from the release from faeces to the aqueous phase. 56 Similar observations were made for macrolides by comparing full-scale WWTP influents and effluents. 106−108 Although significant macrolide amounts have been detected in raw influent solids, 59 alternative hypotheses were made to explain macrolide formation. 109 Release from faecal matter is relevant to CIP and TCY, considering the substantial excretion of these antibiotics in faeces (9%−52%, Table S1 ). 66, 72 Hydrolysis of Particulate and Colloidal Matter. Particulate matter in biological wastewater treatment includes microbial cells, bacterial decay products, exocellular polymeric substances, hydrolyzable and colloidal organic matter and inorganic material. 110−115 Hydrolyzable and colloidal organics undergo hydrolysis by extracellular enzymes, 116, 117 with potential release of sorbed trace chemicals to the aqueous phase. Sorption onto colloidal matter in activated sludge was found significant for hydrophobic chemicals (e.g., polycyclic aromatic hydrocarbons). 111−113 As for pharmaceuticals, little information is available on the sorption onto different matrices. In activated sludge, partitioning of 17α-ethinylestradiol to dissolved and colloidal matter was found to be negligible compared to sludge particles. 118 Nevertheless, partitioning of CIP and TCY to organic constituents other than particulates can be expected relevant, as previously shown for municipal biosolids 119 or purified humic acids. 120 Desorption. CIP and TCY are multivalent zwitterions with strong dipole, having high water solubility and comparably low logD. Nevertheless, both chemicals exhibit significant sorption capacity onto suspended solids and sludge. 121−124 Sorption of these chemicals mainly occurs via hydrophobicityindependent mechanisms (e.g., electrostatic attraction, cation bridging). 119,125−131 Sorption equilibria for CIP are strongly influenced by pH and ionic strength, and can change under varying conditions in biological wastewater treatment. 124 A similar behavior can be postulated for TCY, based on previous observations of pH-dependent sorption in soils. 128 Further observations 33, 122, 132, 133 showed that significant fractions of sorbed pharmaceuticals can be sequestered in the sludge matrix, undergoing slow or no desorption (sorption hysteresis 132 ) and thus not being in equilibrium with the aqueous phase.
Solid Retention Time (SRT). The influence of the solid retention time (SRT) on the elimination of pharmaceuticals has been the object of intense investigation in the past decade. Macroscopically, SRT-related effects were observed in terms of increased pharmaceutical transformation: (i) in the presence of nitrifiers (supported at SRT greater than 5 d in fully aerobic systems and 8−10 d in aerobic-anoxic systems 134 ), as compared to heterotrophs only; 89,135−149 and (ii) in systems with extended physical retention of microbial biomass and thus operating at prolonged SRTs (e.g., membrane bioreactorsMBRs, biofilm reactors). 10,26,33,39,57,58,150−162 In both cases, the influence of SRT could be explained by changes induced in microbial communities, and two hypotheses have been considered to summarize such benefits.
On the one hand, SRT has a positive effect on the microbial diversity by inducing an expansion of the microbial community. This has been demonstrated in laboratory- 163 and full-scale 155 activated sludge systems. Increased biodiversity may stem from the enrichment of slow-growing bacteria 21 (e.g., nitrifiers), specialist degrader strains 155, 164, 165 responsible for specific transformation processes 166 and K-strategists, capable of efficiently utilizing resources at low concentrations. 153, 155 This may translate into an enhancement of the overall biotransformation potential of the community. On the other hand, at prolonged SRT biomass is increasingly exposed to limiting substrate availability conditions, resulting from operation at reduced food-to-microorganism (F/M) ratios. Under oligotrophic conditions, the microbial metabolism of heterotrophic bacteria relies on fortuitous oxidation (resulting from low enzyme specificity) 167, 168 or the utilization of multiple substrates at low concentration (mixed substrate growth). 169, 170 Through broad expression of enzymes responsible of catabolism, bacteria can utilize organic substances not typically used as growth substrates 169−172 (a strategy also referred to as metabolic expansion). 21 In mixed culture systems, extended SRT results in the enrichment of slow-growing nitrifiers and the concomitant exposure of heterotrophs to growth substrate limiting conditions, both likely favorable toward trace chemical biotransformation. For the estrogen EE2, heterotrophic bacteria have been found to biodegrade transformation products generated by ammonia oxidizers, thereby demonstrating an example of cooperative contribution toward the removal of trace chemicals. 89 To date, evidence of the influence of SRT on biotransformation capacity has been disputed or could not be generalized for all pharmaceuticals investigated, 39,42,57,58,87,89,136,139,143,145−148,150,156,158,160,173−178 leading to the conclusion that the impact of SRT may be chemical-specific. In a number of cases, controversial results have been obtained for the same substance (e.g., trimethoprim, 89,137 atenolol 145,173 ), possibly indicating the interference of experimental and methodological approaches used. Among other sources of variability, growth substrate availability (abundance or limitation), growth conditions (batch or chemostat), and the resulting physiological state of biomass may have influenced observations of trimethoprim biotransformation by nitrifiers. 86, 89 In the Supporting Information, we provided a detailed overview of relevant literature investigating the impact of SRT on the elimination of pharmaceuticals and other trace chemicals.
■ FACTORS INFLUENCING THE QUANTIFICATION OR THE PREDICTION OF ANTIBIOTIC REMOVAL IN WWTPS
Influent-Effluent Dynamics and Sampling. The release of down-the-drain chemicals (e.g., pharmaceuticals) into sewer systems and to WWTPs is inherently dynamic. Antibiotics are excreted and discharged in sewer pipelines as a result of discrete toilet flushes, resulting in short-term loading variations. 179−181 Attenuation of fluctuations is shown for substances exhibiting high sorption affinity onto solids in sewers. 182 At wider temporal scale, patterns in loading dynamics to WWTPs have been recognized for several pharmaceuticals and associated with (i) seasonal variations in pharmaceutical consumption and (ii) diurnal variations as a function of their administration patterns and half-life in human body. 42,183−186 Influent generator algorithms have been developed (using stochastic or deterministic approaches) to predict pharmaceutical loading in WWTP influents. 187 Conventionally, the elimination of pharmaceuticals in fullscale WWTPs is calculated or predicted based on influent and effluent concentrations or loads. Capturing loading dynamics in WWTP influents and effluents is therefore crucial for an unbiased estimation of removal efficiencies, and is adequately achieved only by adopting the proper sampling strategy. Load variations, and consequently the selection of the sampling protocol, are influenced by several factors, namely, (i) the type of chemical, its usage and its pathway of discharge in the sewer network (determining the frequency and the shape of pulses through which the chemical is released in the sewer); (ii) the size and shape of the catchment (determining to what extent fluctuations are buffered as a result of in-sewer dispersion); (iii) the type of drainage system employed in the sewer network (determining variations of flow rates in WWTP influents). 180,188−191 According to the guidelines proposed by Ort et al., 188 truly averaged concentrations of pharmaceuticals in influents and effluents of WWTPs serving middle-sized or large catchments can be measured by collecting daily flowproportional composite samples. Additionally, the sampling error can be minimized by appropriately selecting the sampling frequency based on the expected number of pulses. The impact of WWTP residence time distribution on chemical concentrations in effluents may further require pooling of raw influent samples collected in consecutive days. 192 Sampling requirements to determine long-term (e.g., annual) influent loads of antibiotics have been further estimated. 186 Importantly, when assessing removal in specific sections of WWTPs, i.e. only during biological treatment, treatment steps located upstream (e.g., primary clarification) may contribute to reducing load fluctuations as compared to raw influent. 183 For smaller catchments (e.g., hospitals), where the variation of concentrations is expected to be significantly higher due to reduced dispersion (shorter in-sewer residence time) or lower number of pulses expected (limited number of consumers), 193 high-frequency (<5 min) or continuous flow-proportional sampling may be required. 96, 194 Collection and analysis of composite and continuous wastewater samples involves the storage of wastewater in automatic samplers and (typically after filtration) in laboratories under refrigerated conditions (from −20°to 4°C). The stability of trace chemicals, and more specifically antibiotics, during wastewater storage has been investigated elsewhere. 195−197 However, no conclusive evidence exists on the stability of SMX, CIP, and TCY and their human metabolites. Rather high instability of glucuronide conjugates (i.e., morphine-glucuronide) was shown in raw and filtered wastewater at 2°C, and could be prevented by acidification. 195 Nevertheless, the use of acidification during wastewater collection (e.g., by means of preventive acid addition to sampling flasks) has been questioned due to the interference with pH-dependent sorption equilibria of ionizable chemicals, leading to changes in aqueous and sorbed concentrations. 195 Significant release of sorbed amounts to the aqueous phase due to pH decrease may for instance be expected for CIP. 124 Laboratory-Scale Estimation of Process Parameters. Sampling campaigns in full-scale WWTPs are often complemented, if not replaced, with laboratory-scale experiments under controlled conditions. Targeted batch or continuous-flow experiments are used to derive fate parameters (namely, biotransformation rate constants, k Bio , and solid−liquid partition coefficient, K d ), based on which full-scale elimination can be estimated. The reliability of estimated parameters is ensured only if experiments are carried out under environmentally representative conditions. We hereby identified and discussed a number of factors and associated pitfalls, some of which have been addressed elsewhere, 198 influencing observations made on pharmaceutical fate in laboratory-scale wastewater systems.
Underestimation of k Bio by Measuring Parent Pharmaceutical Concentrations in Continuous-Flow and Batch Experiments. By monitoring concentrations of only parent pharmaceuticals in laboratory-scale experiments, retransformation processes leading to the formation of parent pharmaceuticals and thus masking their true elimination are in practice ignored. This may occur in continuous-flow experiments, when monitoring influent and effluent of biological reactors, or in batch experiments, when spiking only parent pharmaceuticals at concentrations similar to indigenous levels of retransformable chemicals.
Over-or Underestimation of Representative k Bio in Batch Tests at Concentration Levels Significantly Higher than in the Environment. Pharmaceuticals, typically prevailing at trace levels in sewage and other environmental media, can be defined as nongrowth substrates. Although early studies 199, 200 showed that laboratory-scale tests at concentrations greater than those in nature may not be representative of conditions typical of natural ecosystems, spiking of reference substances is still common practice. 201 Significant variations in measured removal efficiencies or estimated k Bio , depending on the initial concentration level, were recently shown for several pharmaceuticals in wastewater, for example, ibuprofen, 175, 202, 203 diclofenac, 203 and clarithromycin. 175 A recent detailed study on trimethoprim 204 demonstrated that different spiking levels significantly influenced not only kinetics, but also pathways of biotransformation. Specifically, high concentrations of antibiotics may result in the inhibition of bacteria and/or enzymes responsible of their biotransformation, thus impacting transformation kinetics and pathways (as hypothesized for trimethoprim). 204 No significant variation of biotransformation kinetics (by biomass enriched in synthetic growth medium) was conversely shown at two different spiking levels of salicylic acid and trimethoprim under extant conditions. 142 Over-or Underestimation of k Bio from Experiments Run in the Excess of Growth Substrates. Typically present in wastewater in ng L −1 to μg L −1 concentration levels, pharmaceuticals are considered nongrowth substrates, not providing energy benefit to cells. Biological transformation is regarded as a cometabolic process, whereby primary substrates (COD, nutrients) support biomass growth and energy supply. 145,167,200,205−207 Under conditions of limiting growth substrate availability (e.g., at extended SRT), biotransformation may stem from mixed substrate utilization strategies 169−171 or fortuitous metabolism. 167, 168 Furthermore, growth substrates can competitively inhibit or enhance the biotransformation of trace chemicals, 207 including pharmaceuticals. 32, 33, 198 Spiking of reference pharmaceuticals in batch or continuous-flow experiments involves the addition of carbon (e.g., in the form of methanol), in which spiked substances are dissolved. Biomass is thus provided with excess organic carbon in readily biodegradable form, thereby influencing observations of biological transformation by heterotrophic biomass 198 or ultimately causing a shift in microbial communities even in short-term batch experiments. 208 Underestimation of k Bio by Using Synthetic Growth Medium in Long-Term Experimental Studies. Biotransformation experiments are often conducted with biomass enriched by long-term feeding with synthetic wastewater. Such media often contain a limited range of growth substrates, as compared to real wastewater, thereby influencing the adaptation potential of biomass and minimizing the possible induction of gene expression, responsible for an effective heterotrophic biotransformation, by indigenous chemicals structurally similar to trace analytes. 201, 205, 209, 210 For instance, enhanced estrogen biotransformation rates were found in the presence of recalcitrant organic substrate (mainly bacterial decay and lysis products), typically absent in synthetic media, as compared to reference readily biodegradable substrate. 210 Overestimation of Sorption Coefficients (K d ) by Using Pharmaceutical Concentration in Solids, Possibly Propagating to k Bio Estimates. Pharmaceutical concentrations present in solid phase (e.g., activated sludge) may include a sequestered fraction, not in equilibrium with aqueous concentrations and thus not potentially bioavailable following desorption. Desorption experiments 132, 133 and modeling exercises 33 accordingly showed the significance of irreversibly sequestered fractions of pharmaceuticals in sewage sludge.
The influence of the factors described above on assessing pharmaceutical biotransformation is exemplified in Figure 1 , where estimated k Bio under aerobic and anoxic conditions for a range of pharmaceuticals are presented and compared. We distinguished between k Bio values obtained ( Figure 1a ) in mixed culture experiments with activated sludge and real wastewater, without pharmaceutical spiking 32−34 and (Figure 1b ) in enriched activated sludge fed with synthetic wastewater and spiking of reference substances. 143, 211 In the latter case, more pronounced deviation between aerobic and anoxic k Bio is noticed. Major discrepancies can be noticed, for example, for diclofenac (DCF).
■ MATERIALS AND METHODS
Description and Full-Scale Implementation of ASM-X. In the ASM-X version developed for antibiotics, 32 three states are used to describe the concentrations (ng L −1 ) of different fractions: (i) the dissolved parent fraction (C LI ), (ii) the sorbed parent fraction (C SL ), and (iii) the retransformable fraction (C CJ ). The variable C CJ identifies chemicals undergoing retransformation to C LI via the processes described above. Fate processes include the biotransformation of C LI , retransformation of C CJ back to C LI and sorption (desorption) onto (from) sludge. The parameters used in process rate equations include the biotransformation rate constant, k Bio (L gTSS −1 d −1 ), the retransformation rate constant, k Dec (L gTSS −1 d −1 ), the solid− liquid partition coefficient, K d (L gTSS −1 ), and the desorption rate, k Des (d −1 ). A detailed description of the ASM-X structure, including state variables and parameters, is provided in the Supporting Information (Table S2) .
A parameter is defined to characterize the parentto-retransformable ratio in influent sewage, that is (eq 1),
where C LI,in and C CJ,in denote the influent concentration of parent and retransformable fractions, respectively. The full-scale ASM-X implementation in WEST 2012 (DHI, Denmark), with parameters (k Bio , k Dec , K d , n LI,CJ ) estimated from batch experimental results and evaluated with measurements performed in a 3-day sampling campaign in Bekkelaget WWTP (Oslo, Norway), was used to estimate the elimination of the selected antibiotics. Further details on biological treatment in Bekkelaget WWTP are presented in the Supporting Information and elsewhere. 32, 33, 183 For a meaningful comparison with literature data, scenario simulations were performed using increased or decreased influent loads of pharmaceuticals, as compared to full-scale measurements. 32 Generalization: Concepts. Removal Efficiency Calculation. The full-scale removal efficiency of SMX, CIP, and TCY was calculated based on preclarified and secondary effluent concentrations of these substances. We distinguished between removal efficiency [−] based only on the dissolved parent fraction (parent-based removal efficiency η LI , eq 2)
and on both parent and retransformable fractions (total removal efficiency η TOT , eq 3)
where M denotes chemical mass load (μg h −1 or μg d −1 ), the subscripts "LI" and "CJ" identify parent and retransformable fractions, respectively, and the subscripts "in" and "eff" identify secondary influent and effluent, respectively. Estimated η LI and η TOT were plotted as a function of the normalized influent load of pharmaceuticals (mg h −1 1000 PE −1 ), which was calculated from the influent flow rate (Q in ) and design capacity in terms of PE of the WWTP. We note that the design PE does not correspond to the population served by each WWTP, and is used to allow for a comparison between measured data from differently sized WWTPs and predicted removal efficiencies. Review of Published Removal Data. A literature review was performed to collect removal efficiency data for SMX, CIP and TCY. International data on pilot-and full-scale removal of pharmaceuticals were included in this study only if the corresponding literature source responded to a number of criteria: (i) the wastewater sampling protocol used was explicitly reported and data presented were obtained by applying sound sampling techniques (see Influent−Effluent Dynamics and Sampling section), based on information provided in the publication; (ii) removal efficiencies during secondary treatment could be calculated, where not explicitly reported, from published data (e.g., concentrations in secondary influent and effluent); (iii) additional information on the WWTP assessed was sufficiently detailed, including average influent flow rate of the WWTP or influent flow rate in the sampling period, HRT, SRT, and the design capacity in terms of PE. To our knowledge, a number of literature studies 46, 55, 56, 104, 105, 121, 159 complied with these criteria. These studies investigated pharmaceutical elimination in conventional activated sludge (CAS), fixed bed biofilm reactors (FBR) and membrane bioreactors (MBR). In addition, measurements by Yang et al. 212 in secondary WWTP influent were used to discuss variability of the parameter n LI,CJ (eq 1) in full-scale WWTPs. Further details on full-scale WWTPs and catchments investigated in the mentioned literature studies are presented in the Supporting Information (Tables S5−S6) .
Zero-Catchment Scenario. Literature studies on in situ treatment of hospital effluent were selected to characterize a "zero-catchment" scenario, describing the removal of pharmaceuticals in WWTPs with negligible upstream sewer transport. Literature data 96, 213, 214 were used to assess antibiotic removal in WWTPs treating hospital wastewater (MBR, hybrid biofilmactivated sludge, HYBAS and moving bed biofilm reactor, MBBR respectively) and compared with ASM-X predictions. In this way, we aimed at addressing the potential impact of retransformation processes, not occurring in upstream sewer but only via biological treatment, on the observed elimination. As hospital WWTP capacity is usually expressed in terms of hospital beds, predictions and measured data were compared assuming that 1 bed was equivalent to 3.4 PE 96 based on the wastewater production per bed in the study and the wastewater production per PE (200 L d −1 PE −1 ). 215 Presentation of Results. ASM-X generalization was performed by plotting estimated η LI and η TOT against the normalized influent load of pharmaceuticals. An optimal way to present these results was found in operating plots that were constructed using 6-h average influent loads and removal efficiency ( Figure S5 ). 33 In this way, we accounted for two crucial factors, influencing the calculation of removal efficiencies: (i) dynamics in the influent loads of pharmaceuticals, observed during the sampling period; and (ii) residence time and consequent dispersion effect in the simulated WWTP. 192 Removal efficiency predictions were presented under a range of loading conditions, and could be used for comparison with literature removal data, usually referred to 24-h up to 3-d composite samples. In Figure S5 , predicted removal efficiency curves are defined using the mean of predictions (dashed black line) and an uncertainty interval (light or dark gray) based on standard deviation of 6-h removal efficiency predictions. Examples of the interpretation of operating plots are directly provided in the Results and Discussion section and further details are given in the Supporting Information.
Dynamic Risk Assessment. A preliminary assessment of the environmental risk, associated with the release of residual pharmaceuticals to surface water, was performed. Based on ASM-X predictions, 32 predicted environmental concentrations (PECs) were estimated from Bekkelaget secondary effluent concentration (eqs 4 and 5)
where C LI,eff and C CJ,eff (ng L −1 ) denote the measured secondary effluent concentrations of parent and retransformable fraction, respectively. We distinguished between PECs accounting for only effluent C LI (PEC LI ) and for both effluent C LI and C CJ (PEC TOT ). A default dilution factor (DF) of 10 was assumed for the estimation. 216 Quasi-MECs (concentrations in freshwater estimated from measurements in WWTP effluent 1 ) were also estimated from measured C LI in secondary effluent. 32 PECs and quasi-MECs were finally compared to predicted no-effect concentrations (PNECs) reported in literature, describing threshold concentrations for risk in receiving water bodies. Risk was associated with a pharmaceutical in Bekkelaget effluent when the ratio between PEC (or quasi-MECs) and PNEC (also known as risk quotient, RQ) was greater than 1. Additionally, the dynamics in effluent concentrations (and therefore, in PECs ■ RESULTS AND DISCUSSION Sulfamethoxazole (SMX). Removal in Full-Scale WWTPs. The elimination of parent SMX has been previously investigated in conventional and advanced biological full-scale WWTPs. Biotransformation has been recognized as the main elimination mechanism of SMX, 32, 55, 56, 123, 159 with minor contribution from sorption onto sludge. Among all conjugated metabolites of SMX, detailed evidence on the full-scale removal of only N 4 -acetyl-SMX is available. 55, 56 Sorption of N 4 -acetyl-SMX was found to be negligible because of its high solubility and polar nature (typical of conjugated metabolites). Considering the absence of measurements on other conjugated metabolites of SMX, namely SMX-N 1 -Glu, the retransformable fraction C CJ of SMX in literature studies was assumed to be entirely represented by N 4 -acetyl-SMX. We accordingly compared predicted η TOT with the combined removal efficiency of SMX and N 4 -acetyl-SMX (also referred to as η TOT in Figure 2 ). Table S5 . Measured removal efficiencies denoted as η TOT include the elimination of parent SMX and the conjugated metabolite N 4 -acetyl-SMX. Scenario simulations to derive predicted η LI and η TOT in panels a, b−c, and d were run considering a 1.25-, 5-, and 25-fold increased influent load, respectively. Scenario simulations to derive predicted η LI and η TOT at extended SRT in panel c were run assuming k Bio = 3 L gTSS −1 d −1 .
In Figure 2 , ASM-X removal efficiency predictions (shaded curves) are compared with measured removal efficiency (data points) for SMX (and N 4 -acetyl-SMX, where possible). Predicted removal efficiency (η LI and η TOT ) curves were obtained simulating a 1.25-fold (Figure 2a ) and 5-fold (Figure 2b−c) increased influent loading of SMX as compared to Bekkelaget WWTP. For a meaningful comparison, we distinguished between literature studies assessing the elimination of parent SMX only (Figure 2a ) and literature studies assessing the elimination of both SMX and N 4 -acetyl-SMX in WWTPs operating at SRT lower than and 16 d ( Figure 2b ) and higher than 16 d (Figure 2c ). A threshold of 16 d represents the SRT, at which Bekkelaget WWTP was operated during the sampling campaign used for ASM-X evaluation. 32, 33 Overall, a large variability in measured removal efficiency for SMX (from −150% to 80%) is evident from published data. To explain the observed variability, studies assessing only the elimination of parent SMX 46, 159 are first considered (Figure 2a ). Measurements are well approximated by η TOT predictions, indicating limited impact of retransformation during secondary treatment as a result of low influent C CJ concentrations. This hypothesis is supported by (a) the significant formation (+45%) of SMX during primary settling; 46 (b) the input load contribution from pharmaceutical manufacturing to the WWTP investigated; 159 (c) reduced concentrations of conjugates of other sulfonamides (acetyl-sulfamethazine) in the primary effluent in the same WWTP; 217 (d) the size of the WWTPs investigated (Table S5) , serving medium-to-large-sized catchments with likely retransformation in upstream sewers. The significance of (d) is discussed later in the manuscript.
ASM-X predictions of η LI and η TOT are in close agreement with removal efficiencies for SMX and SMX + N 4 -acetyl-SMX, respectively, reported for Kloten−Opfikon WWTP 55, 56 (CAS 1, Switzerland; SRT < 16 d; Figure 2b ). Low or negative η LI (from −107% to 9%) occurred as a result of the almost complete retransformation, through deconjugation, of N 4 -acetyl-SMX back to parent SMX. The underestimation error between η LI and η TOT in Kloten-Opfikon (from −160% to 44%) was in the error range predicted by ASM-X (from −200% to 60%). The good agreement between measured (including N 4 -acetyl-SMX as the only conjugate) and predicted η TOT indicates that the retransformable fraction in WWTPs may be almost completely represented by the acetylated conjugate. Accordingly, estimated k Dec values 32 well approximate biotransformation rate constants for N 4 -acetyl-SMX in activated sludge (Table S4 ). The other conjugated metabolite SMX-N 1 -Glu may undergo (i) extensive and fast retransformation in upstream sewers, with negligible presence in WWTP influent or (ii) limited retransformation (and elimination) during biological wastewater treatment. Figure 2c presents η LI and η TOT predictions and measurements in WWTPs operating at SRT higher than or equal to 16 d (16−80 d). Although SRT is not determined for attached growth systems, removal efficiency data measured in FBR 56 were also considered. Significant variability is shown for measured η LI (from −138% to 60%) due to observations in CAS2 WWTP. Minimum η LI for CAS 2 (−138%) and FBR (−61%) occurred when comparably higher loads of N 4 -acetyl-SMX (n LI,CJ = 0.15) occurred in secondary influent. Again, the reported data highlight the significant underestimation error arising by characterizing SMX removal only based on parent SMX concentration. Importantly, measured η LI and η TOT included in Figure 2c showed an overall increase when compared to what presented in Figure 2b . Measured η TOT (60%−76%) in CAS 2 and FBR were generally higher than in CAS 1 (from −1% to 53%). In addition, measured η LI (37%− 40%) and η TOT (70%−90%) in MBR (SRT = 16−80 d) 56 were consistently higher than for CAS1 ( Figure 2b ) under similar loading conditions (the two systems were operated in parallel). As a consequence, most of the measured η LI and η TOT were higher than respective prediction curves, indicating that retransformation per se may not explain the variability in observed removal efficiencies. We hypothesized that a kinetic improvement of SMX biotransformation occurred in WWTPs operated at SRT ≥ 16 d. A scenario simulation with ASM-X was performed assuming increased biotransformation rate constant for parent SMX (k Bio = 3 L gTSS −1 d −1 ; Figure 2c , "High SRT" curves) to estimate and reproduce enhanced η LI and η TOT . The obtained predictions were selected to describe the highest measured removal efficiencies (MBR with SRT < 20 d). 56 The estimated k Bio is a comparably high value and the simulated increase possibly lumps other effects. We note that the increased biomass concentration at which MBRs are typically operated (2−3-fold higher TSS than in conventional WWTPs) cannot alone explain the observed enhancement in SMX elimination. Accordingly, no further increase of η LI or η TOT as a function of SRT was observed (at SRT > 16 d) in the MBR. 56 Overall, the model-based assessment of SMX elimination in WWTPs suggests that the variability of observed removal efficiency can be associated with the influence of conjugated metabolites (namely, N 4 -acetyl-SMX) in secondary influents and of the SRT set for WWTP operation. Such conclusions were drawn only when removal of SMX and N 4 -acetyl-SMX were simultaneously assessed, and could be used to explain observations in other WWTPs. 46, 159 Zero-Catchment Scenario. Figure 2d presents η LI and η TOT curves predicted with ASM-X (25-fold increased influent loading of SMX compared to Bekkelaget WWTP), and published removal efficiency measurements. 96, 213, 214 In these studies, a pilot MBR (SRT = 30−50 d, TSS = 2 g L −1 ) and two biofilm systems (HYBAS and MBBR), respectively, were operated for decentralized treatment of hospital effluent. In one study 96 aqueous concentrations of both SMX and N 4 -acetyl-SMX were measured, allowing for the calculation of η LI and η TOT . The deviation between η LI and η TOT was also in this case significant (from 22% to 72%), in the error range predicted by ASM-X. Both η LI (from −53% to 26%) and η TOT (from 6% to 48%) were lower than in the previously assessed MBR but comparable to efficiencies achieved in CAS and FBR systems. Measured η LI data from the three studies were generally underpredicted by η LI curve, whereas measured η TOT data points were located on or below the corresponding η TOT curve. Considering the significant elimination of N 4 -acetyl-SMX (81% ± 4%), the absence of catchment between the hospital effluent and the pilot MBR could only to some extent explain the observations. Influent n LI,CJ to the MBR (≥1 g LI g CJ −1 ) was on average higher than in urban catchments 32, 55, 56 and excreted ratios expected from human pharmacokinetics ( Figure S1 ). Comparably lower concentrations of N 4 -acetyl-SMX in secondary influent may therefore explain the generally higher η LI measurements as compared to ASM-X predictions. No evidence of deconjugation in the primary clarifier, located upstream to the MBR, was reported, 96 indicating that specific n LI,CJ ratios were intrinsic to the hospital effluent (excluding that retransformation occurred during sample storage and handling). We provided a possible interpretation of observations by comparing n LI,CJ data from municipal and hospital WWTPs (see Impact of Retransformation/In-Sewer Retransformation section, Figure 3 ). As shown by the comparison between measured and predicted η TOT , the extended SRT in MBR, HYBAS, and MBBR could not explain the enhancement of parent SMX elimination.
Impact of Retransformation/In-Sewer Retransformation. By comparing measured removal efficiencies to η LI and η TOT prediction curves (Figure 2) , it was possible to quantify the impact of retransformation from SMX conjugates back to parent SMX in pilot-and full-scale biological WWTPs. Variability in measured SMX removal efficiencies was explained by different parent-to-retransformable ratios (n LI,CJ ) in secondary influent due to transformation processes in sewer networks upstream of WWTPs. To date, in-sewer biological transformation processes (or "reactive sewer" concept) have been systematically evaluated only for limited chemical groups, for example, estrogens and their excreted conjugates. 40, 69, 218 On the contrary, in-sewer processes have been considered not relevant for antibiotics, 186 whereas recent evidence 219 showed significant formation of SMX (+66%) during transport in pressurized sewer pipelines.
The extent of in-sewer retransformation of SMX conjugates likely depends on: (i) the mean hydraulic retention time of raw sewage in sewer pipelines; and (ii) redox conditions prevailing in sewer systems. Very little evidence is available as to point (ii) because only anaerobic conditions have been assessed 219 and no information on transformation kinetics in raw sewage is available. Mean residence times in upstream sewers are also not typically reported in full-scale fate studies, making an evaluation of their impact challenging.
Therefore, we evaluated the variability of n LI,CJ for SMX in worldwide full-scale WWTP influents as a function of the WWTP design capacity (in PE) (Figure 3) . It was again assumed that the retransformable fraction of SMX (C CJ ) would coincide with N 4 -acetyl-SMX concentration. The design capacity is used here as an approximation of the catchment size and is considered as a surrogate indicator of the mean residence time in sewer systems. Our evaluation did not aim at establishing mathematical correlations, and is based on a number of assumptions/simplifications: (a) redox conditions do not influence kinetics of SMX retransformation, as preliminarily confirmed by k Dec values from various literature sources (Table S4 ); (b) SMX consumption and excretion is homogeneously distributed within a catchment; (c) differences in residence time in gravity and pressurized sewers are not considered; (d) differences in population density within studied catchments are insignificant. A preliminary assessment showed that the design capacity can give an indication of in-sewer mean residence time (Table S7) . Measured n LI,CJ in both raw and preclarified sewage were included (Figure 3) , considering evidence of deconjugation in primary settlers. 46, 55, 56 Measured n LI,CJ were compared with the range of expected ratios at the excretion point. 53, 220 We first considered n LI,CJ in the influent of full-scale municipal WWTPs (design capacity > 10 000 PE). Measurements by Gobel et al. 55, 56 approximated theoretical excreted ratios, indicating limited retransformation in a small-sized catchment (Table S7 ). A similar ratio was estimated for a larger catchment (WWTP capacity = 281 000 PE) using a modelbased assessment. 32 Significantly higher n LI,CJ (>2 g LI g CJ −1 ) was measured in the secondary influent of large WWTP 212 (capacity = 1 000 000 PE), indicating that extensive retransformation may have occurred upstream to the sampling point. These preliminary findings suggest that influent composition in terms of parent and retransformable fractions, and thus the extent of retransformation upstream to secondary treatment, may depend on the catchment size. This could further explain the observation of higher η LI measurements (comparable to predicted η TOT ) in WWTPs with 277 000 PE 159 and 740 000 PE 46 (Figure 2a ).
Measured n LI,CJ in raw and preclarified hospital effluent 96 were generally found higher than theoretical ratios at the excretion point, thus explaining the underestimation of η LI measurements 96, 213, 214 by ASM-X predictions (Figure 2d ). This evidence was not expected based on our hypothesis that negligible in-sewer transport would correspond to limited retransformation upstream to secondary treatment. We explored alternative interpretations, focusing on SMX consumption and excretion in hospitals and households. The fraction of SMX consumed or excreted in hospitals, compared to the overall consumption/excretion in a specific catchment, exhibits significant geographical (Norway, < 1%; 221 Australia and Italy, < 10%; 194, 222, 223 Germany, 12%−18%; 224 Switzerland, 16%−52%; 225 Denmark, ∼100%, medstat.dk for year 2013) and temporal variations. 225 Even when administration occurs in hospitals, not negligible fractions of pharmaceuticals may still be excreted in households because of specific treatments or reduced hospitalization periods. 194, 226 Thus, only a limited fraction of pharmaceuticals administered in hospital effectively reaches hospital effluents. Pharmacokinetic studies have indicated slower elimination of N 4 -acetyl-SMX (i.e., longer half-life) from human body than of parent SMX in healthy 54, 227 and renally impaired subjects. 228 Accordingly, relative excreted amounts of SMX and N 4 -acetyl-SMX in urine vary from the initial hours (e.g., in hospitals) to 48−96 h (e.g., in households) after administration and, more importantly, higher n LI,CJ can be expected in hospital sewage. Notably, theoretical n LI,CJ at the excretion point, derived from data in Table S1 , represent average values over 60−96 h after SMX administration.
Overall, our observations point at the following conclusions: (i) the impact of SMX formation during wastewater treatment is more pronounced in small urban catchments/WWTPs, where limited retransformation in upstream catchments is expected, and (ii) temporal trends for the excretion of SMX and its conjugated metabolites may have a significant impact on loads entering WWTPs that treat hospital sewage.
Impact of SRT and MBR Operation. By comparing predicted and measured 56 η LI and η TOT , it was possible to identify enhanced removal efficiencies in municipal CAS, FBR, and particularly, MBR WWTPs (SRT = 16−80 d). For the MBR system, a comparison with removal efficiencies in a CAS WWTP operated in parallel confirmed that variability in observations was not due to different n LI,CJ ratios in influent. Considering the almost complete removal of N 4 -acetyl-SMX (>80%) in all WWTPs investigated, a kinetic improvement of SMX biotransformation at SRT > 16 d likely caused the enhanced SMX elimination. Through scenario simulations, we suggested that improved biotransformation kinetics resulted from a step increase of k Bio , in agreement with previous findings for diclofenac. 33 In previous studies at SRT > 100 d, 175, 176 estimated k Bio values for SMX for laboratory-and pilot-scale MBRs were found comparable to CAS (see Table S4 for comparison). This may though be considered as limited evidence of the influence of extended SRT on biotransformation kinetics of SMX. Improved SMX elimination may be alternatively attributed to higher TSS concentrations, at which MBRs are typically operated. 161 Notably, k Bio values estimated to date (Table S4) were normalized by the total biomass content (as TSS or VSS), not accounting for the reduction of the active biomass fraction at increasing SRT. 57 Thus, it should not be excluded that the biotransformation capacity of active biomass may be enhanced at prolonged SRT (as a result of increased biodiversity or improved metabolic capabilities)a hypothesis that could be demonstrated only by assessing k Bio normalized by active biomass.
Overall, currently available evidence is still limited to provide a valuable explanation of observed SMX elimination and thus to support the hypothesis proposed in this study.
Ciprofloxacin. Removal in Full-Scale WWTPs. The fate of CIP was investigated in CAS WWTPs, 104, 105, 121 where the elimination almost entirely occurred via sorption onto activated sludge. In Figure S6a , ASM-X prediction curves for η LI and η TOT were compared to measured removal efficiencies only for parent CIP. 104, 105, 121 Scenario simulations with ASM-X were run assuming reduced influent loading (1/30th of original loading 32 ). Sorption equilibria in activated sludge were simulated using the Freundlich isotherm equation (eq 6)
where X SS (gTSS L −1 ) denotes the TSS concentration of activated sludge and experimental values for the Freundlich coefficients K f (10.6−10.7 μg 1−n L n g −1 ) and n (0.62−0.73) under anoxic and aerobic conditions were used. 124 Implementation of eq 6 in ASM-X rate equations is presented in Table S2 . Measured CIP removal efficiencies were in good agreement with ASM-X predictions for η TOT , indicating limited retransformation and/or negligible concentrations of the retransformable fraction (C CJ ) in the WWTPs investigated. Experimental and modeling studies 13,59,104,105,121,229,230 showed the presence of relevant amounts of CIP sorbed onto influent and effluent solids. To further assess ASM-X predictions when accounting for sorbed fractions, further scenario simulations were run, assuming (i) negligible retransformable fraction in the influent (C CJ,in = 0); (ii) sorbed CIP concentrations in secondary influent solids based on measured influent TSS and CIP concentrations 32 and K d = 2 L gTSS −1 for primary sludge. 105, 121 On the basis of ASM-X predictions, we calculated a removal efficiency (η TOT,X ) that accounts for influent and effluent loads of CIP sorbed onto solids (eq 7):
where M SL,in and M SL,eff denote the mass loads of sorbed CIP onto secondary influent and secondary effluent solids, respectively, and M LI,in and M LI,eff the mass loads of parent CIP in secondary influent and effluent, respectively. Similarly, reported CIP concentrations in sorbed phase were used to calculate measured η TOT,X from full-scale investigations. 104, 105, 121 Predicted η LI and η TOT,X were in good agreement with measured CIP removal efficiencies ( Figure S6b−c) . The deviation between η LI and η TOT,X is shown to be rather small for ASM-X predictions (0%−2%) and some of the full-scale measurements (4%−5% 105, 121 ), whereas significant deviation (35%) was also reported. 104 Although small compared to SMX, the variability of measured η LI and η TOT,X for CIP may be attributed to uncertainties intrinsic to analytical methods, in particular to the extraction and quantification in solid matrices. 231 Zero-Catchment Scenario. CIP elimination was also investigated in MBR treating hospital sewage. 96 Measured removal efficiencies, only referring to CIP in the aqueous phase, were compared to ASM-X predictions for η LI and η TOT ( Figure S7a ). Scenario simulations were performed assuming 4-fold increased influent loading using a Freundlich-based sorption model (see above). Measured η LI (29%−72%) were close to η TOT predictions, being significantly higher than predicted η LI (lower than −150%). In analogy with findings for full-scale WWTPs (Figure S6a ), our results suggest insignificant retransformation or alternatively the presence of negligible retransformable CIP fraction. CIP removal prediction was consequently assessed via new scenario simulations with ASM-X, considering the retransformable fraction in secondary influent negligible (C CJ,in = 0) and the presence of sorbed CIP concentration in secondary influent solids (K d = 2 L gTSS −1 ). New η LI (and η TOT,X , accounting for sorbed fractions in influent and effluent) predictions were obtained, in agreement with measured η LI ( Figure S7b ). We note that removal efficiencies measured in the hospital MBR ( Figure S7) were on average lower than in full-scale WWTPs ( Figure S6 ). CIP concentration in sorbed phase was not measured, preventing a complete mass balance. Nevertheless, reduced removal efficiency may be attributed to less efficient sorption (resulting from competition for or progressive saturation of sorption sites by pharmaceuticals at μg L −1 levels) or to the presence of conjugates (sulfo-CIP) in influent. CIP elimination was also investigated in a fullscale WWTP (primary clarification + MBR) treating hospital effluent. 232, 233 The investigation highlighted (a) the relevance of sorption as removal mechanism and (b) an ∼10% deviation between theoretical excreted CIP loads and influent loads to WWTP, possibly corresponding to the amounts of CIP excreted in faeces and/or in conjugated form (sulfo-CIP) ( Figure S4 and Table S1 ).
Tetracycline. Removal in Full-Scale WWTPs. Elimination of TCY during biological wastewater treatment occurs via sorption onto solid matrices (e.g., sludge), with limited contribution from biotransformation. 32, 122, 123 As previously described for CIP, TCY exhibits significant affinity to solids despite its low hydrophobicity (log D = −1.25 at pH 7; ACD/ Laboratories LogD). To our knowledge, no study documenting TCY elimination during secondary wastewater treatment satisfied the criteria set in this study for preliminary data screening, e.g. the use of adequate sampling protocols. The relevance of residual TCY in WWTP effluents for environmental risk assessment was thus discussed based only on simulation results (see following paragraph). Evidence from batch studies 32, 122, 123 suggests significant TCY removal from the aqueous phase, as confirmed by full-scale measurements 32 (η LI = 77% ± 8%). Similarly to CIP, variability in removal efficiency determinations for TCY may be expected due to uncertainties associated with analytical methods, including, for example, the quantification of TCY in solids and of matrix effects in influent and effluent wastewater. 231, 234 Implications for Environmental Risk Assessment. Environmental risk assessment (ERA) methodologies are used to characterize the potential risk for ecological receptors from the exposure to toxic chemicals released in the environment. ERAs rely on the prediction of environmental concentrations (PECs) at regional or local catchment level using a range of modeling tools 235 and on their comparison to PNECs derived from ecotoxicological experiments. Guidelines for ERAs of pharmaceuticals have been proposed by the European Medicines Agency (EMA) with integration from the REACH (Registration, Evaluation, Authorisation, and Restriction of Chemicals) framework regulation. 236 Emissions from WWTPs to receiving water bodies are recognized as one of the major sources of ecological exposure to pharmaceuticals.
A number of recommendations for the improvement of these guidelines have been recently proposed. 237−241 Importantly, ERAs are typically conducted by simulating nondynamic release of pharmaceuticals from WWTPs, thus estimating steady-state PECs. This appears to be a rather simplified approach when considering (a) significant intraday variations in effluent loads and concentrations of antibiotics; 183, 242 (ii) differences in antibiotic consumption rates over the year. 225 In addition, the release of retransformable pharmaceutical fractions may represent an additional source of risk, due to the potential formation of parent pharmaceuticals in freshwater. Inclusion of retransformable metabolites in ERA had been previously recommended for estrogens. 50, 243 Considering these shortcomings, we present here an example of ERA where dynamics in PECs and the contribution of the retransformable fraction are accounted for when assessing environmental risk in surface water. Specifically, we present ( Figure 4 ) the results of a preliminary ERA on the release of TCY to receiving surface water from Bekkelaget WWTP effluent. Quasi-MECs, PEC LI and PEC TOT were calculated based on three-day monitoring and modeling predictions 32 and compared to PNEC (acute toxicity data 1 ). Two major evidence sets are highlighted: (i) the significant variations of quasi-MEC and PEC LI , temporarily exceeding the PNEC threshold in the three-day time interval; (ii) the potential contribution of the retransformable fraction to PEC TOT and thus to the overall risk associated with TCY. We note that our evaluation as to point (ii) should be considered as speculative, since TCY retransformation could not be addressed in this generalization study by comparing ASM-X predictions to international full-scale measurements. Furthermore, simulation results should be regarded as preliminary since a fixed dilution factor was assumed and more complex hydrodynamic phenomena (downstream transport, dispersion) were not considered. Nevertheless, considering dynamics in WWTP effluents and monitoring through multiple days may be relevant for improvement of risk assessment protocols, especially for acute toxicity effects and in freshwater streams having significant contribution from WWTP effluents. 237 In addition, the presence of potentially retransformable fractions of pharmaceuticals can amplify the ecological risk, and this hypothesis requires further investigation. . Dynamic risk assessment of TCY in surface water considering only parent (C LI ) and parent + retransformable fractions (C TOT = C LI + C CJ ) released from WWTP. PEC LI (green solid line) and PEC TOT (black dashed line) were calculated from ASM-X predictions for effluent TCY (dilution factor = 10 216 ). PNEC of parent TCY was obtained from acute toxicity data. 1,221 Quasi-MECs (circles) were estimated from measured parent TCY concentrations in Bekkelaget WWTP effluent. 32 The evaluated time interval (3 d) refers to the full-scale monitoring of Bekkelaget WWTP, used also for ASM-X validation. 32 elimination were assessed using the Activated Sludge Modeling framework for Xenobiotics (ASM-X) and measured removal efficiency data obtained in pilot-and full-scale WWTPs.
First, we showed that retransformation, as a result of metabolite deconjugation, can significantly impair the elimination of SMX in full-scale WWTPs. The extent of retransformation in different WWTPs was adequately predicted by ASM-X and likely explains the observed variability in SMX removal efficiencies. The combined quantification of parent and conjugated pharmaceuticals is thus required to close mass balances in WWTPs, as deconjugation is a relevant process to a number of pharmaceuticals (among others, carbamazepine, diclofenac, and sulfonamide antibiotics). Furthermore, we could determine whether retransformation is expected to prevail during secondary treatment or in upstream sewer systems. Among the responsible factors we identified the catchment size, with extensive retransformation in sewer systems of larger catchments. Different excretion patterns of SMX and its conjugated metabolites in hospitals and households were considered to explain observations in a WWTP treating hospital sewage, with negligible upstream in-sewer transport. This further indicates that substantial amounts of antibiotics administered in hospitals are not excreted to hospital sewage (but, e.g., in households), as confirmed in a recent nationwide study. 226 The generalization of ASM-X predictions with full-scale measurements further suggested a step enhancement of SMX biotransformation kinetics undergo at SRT ≥ 16 d, thereby resulting in improved SMX elimination in full-scale WWTPs and in agreement with previous evidence for diclofenac. 33 Currently available experimental evidence is not sufficient to confirm this finding, and further research may be required for the quantification of transformation kinetics in treatment systems (MBRs, biofilms) operating at extended SRT. 244 Retransformation processes were shown to be not significant for CIP fate in biological treatment systems, even though limited empirical evidence in full-scale WWTPs was available to confirm this conclusion. ASM-X predictions allowed estimating the significance of sorbed fractions in influent and effluent solids when determining CIP removal efficiency.
Using TCY as an example, we showed that dynamics in effluent loading and the presence of residual retransformable fraction can have significant implications on the assessment of the environmental risk in surface water. Conclusions as to the significance of the retransformable fraction have not yet been corroborated by empirical evidence, and further research (combining full-scale measurements and model predictions) is required to address this question for this and other pharmaceuticals.
The presented methodology is relevant to the prediction of: (i) WWTP elimination of other pharmaceuticals presenting similar characteristics to the ones assessed in this study (e.g., sulfonamides, consistently present in wastewater in acetylated form); and (ii) maximum removal efficiencies of pharmaceuticals in full-scale WWTPs, thus complementing laboratory-scale experimental studies. 245 Overall, our findings suggest the adoption of an integrated approach for the evaluation of antibiotic removal in full-scale WWTPs, where excretion and in-sewer fate processes are considered within the boundaries of the systems investigated.
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